Physician profile
Vannessa Evans
NPI 1467968099
$2,474.07
in general payments reported to CMS, 2019-2025
25 companies · $18.87 in 2025
The $18.87 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $744 · 2021: $1,095 · 2022: $48.43 · 2025: $18.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.06 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $443.03 | 2019-2021 | |
| Abbvie INC. | $253.15 | 2020-2021 | |
| Astellas Pharma US INC | $167.62 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $147.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $125.12 | 2021 | |
| Lilly USA, LLC | $118.97 | 2019-2021 | |
| Amarin Pharma, INC. | $92.36 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $84.85 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $62.73 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.97 | 2019-2021 | |
| Celgene Corporation | $48.43 | 2022 | |
| Paratek Pharmaceuticals, INC. | $45.95 | 2021 | |
| Eisai INC. | $44.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.15 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $40.01 | 2021 | |
| Pfizer INC. | $33.16 | 2021 | |
| Glaxosmithkline, LLC. | $25.80 | 2019-2020 | |
| Allergan, INC. | $24.44 | 2020 | |
| Amgen INC. | $21.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.72 | 2019 | |
| Gilead Sciences, INC. | $18.87 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.84 | 2019 | |
| Genentech USA, INC. | $14.71 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vannessa Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.